Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Myeloma Drug Access Limits Unlikely Near-term – Aetna, Express Scripts Say

This article was originally published in The Pink Sheet Daily

Executive Summary

ICER’s cost-effectiveness assessment won't lead to place step therapy restrictions on sequence of multiple myeloma treatment regimens – at least until there's better data.

You may also be interested in...



Ovarian Cancer Drugs Will Get ICER Review As Olaparib's Maintenance Indication Looms

PARP inhibitors from Tesaro, Clovis, and AstraZeneca have been tentatively chosen for the evaluation.

Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control

With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.

Medicaid Spending On Accelerated Approvals ‘Outsized’ Relative To Use

A new study highlights a subset of high-cost drugs in Medicaid for which legal and policy tools may be available to manage spending growth.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel